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Introduction
Mycolic acids (MAs) are characteristic components of the cell envelopes of mycobacteria, often covalently bound to arabinogalactan as a penta-arabinose tetramycolate. [1] [2] [3] They are also seen as trehalose dimycolate (TDM -a potent signalling agent in the immune system), 4 ,5 trehalose monomycolate (TMM) 6 and other sugar esters that are not bound to the cell wall, [7] [8] [9] or as free mycolic acids. 10 MAs comprise two elements (Figure 1) , the β-hydroxy-acid, for which d is generally 21 or 23, and the meromycolate. The latter is a long chain usually containing two groups X and Y. In the most common classes of mycobacterial MA, the two groups are both cis-cyclopropanes (α-MA), or group X is an α-methyl-β-methoxy or α-methyl-β-keto group (methoxy and keto-MA respectively). MAs are generally present as complex mixtures containing several different chain lengths of each class, and the detailed composition is dependent on the mycobacterium. 11, 12 The presence and proportion of individual classes of MA is important for the virulence of diseases such as tuberculosis. 13, 14 The MAs are themselves strongly bioactive and indeed individual - 15 In addition, there are a range of generally less abundant MAs in mycobacteria containing other X and Y groups; these include molecules containing an α-methyl-transalkene unit. 11, 12 Keto-mycolic acids 2 with a proximal trans-alkene substituent and a variety of chain lengths have been reported (Table 1) . 11, 12, [16] [17] [18] In these cases, the methyl group adjacent to the alkene is on the proximal side relative to the hydroxy-acid. The methyl group in the X position of keto-and methoxy-MA and at the Y-position in α-methyltrans-cyclopropane containing MA, is distal from it. 11, 12 
-------------------------------------------------------------------

M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
hydroxy-mycolate. 20 In addition, related methoxy-MA 3 have been reported as in Table 2. 11 Table 2 . Typical chain lengths of major β-methyl-trans-alkene containing mycobacterial methoxymycolic acids (3) The biosynthesis of these and other MA has been studied extensively. [21] [22] [23] [24] [25] [26] [27] Labelling studies show the methyl branch of trans-MA from M. tuberculosis are exclusively on carbons derived from the 2-position of acetate, while those from M. smegmatis, are exclusively derived from the 1-position. 28 Another type of mycolic acid, isolated from M. smegmatis and Mycobacterium aurum, 29 Mycobacterium chelonei, 30 and Mycobacterium fortuitum, 31 contains an α-methyltrans-alkene at the proximal position and a cis-alkene at the distal position. [32] [33] [34] In the latter case, the specific rotation of its methyl ester has been reported to be +1.4 (CHCl 3 ), 35 while that of the acetoxy methyl ester is reported as +3 (CHCl 3 ) , and that of a deacetoxy derivative of a mycolate containing only an α-methyl-trans-alkene chiral centre corresponds to a molecular rotation (M D ) of -19.5. 35 In addition, the specific rotation of a wax ester containing this unit has been reported to be +4.3 (CHCl 3 ). 29, 36, 37 This allows the contribution to the molecular rotation from the α-methyl-trans-alkene to be calculated, as the only other chiral centres in these cases are at the hydroxy-acid position, the contribution of which to the molecular rotation is known (+40°). This leads to a value of -25° for the α-methyl-trans-alkene (for 30% of methyl branched molecules); this in turn suggests this sub-unit has an (R)-stereochemistry, based on model compounds. 18 As part of a study to determine the biological significance of specific MA structures, [38] [39] [40] [41] [42] [43] [44] and to confirm regio-and stereochemistry, we now report the synthesis of hydroxy-MA, keto-MA and methoxy-MA containing a α-methyltrans-alkene unit. Four sugar esters and one glycerol ester were prepared from one methoxy-MA, to provide the opportunity for a systematic comparison of their effects on cytokines and chemokines, as well as their application as antigens in the serodiagnosis of tuberculosis.
2.
Results and discussion As the first step in the synthesis of alkene-MA 23, 6-bromohexanal (4) was chain extended to the ester 6 and then converted into the sulfone 7 (Scheme 1): Scheme 1: (i) LiHMDS, THF (71%); (ii) H2, Pd/C, EtOAc/EtOH (88%); (iii) 1-phenyl-1H-tetrazole-5-thiol, K2CO3, acetone (86%); (iv) H2O2, (NH4)6Mo7O24.4H2O, THF/IMS (95%)
In order to fix the (R)-stereochemistry of the α-methyltrans-alkene fragment, aldehyde 8, 39, [45] [46] [47] was chainextended with compound 7 and base, using a modified Julia-Kocienski reaction, [48] [49] [50] followed by hydrogenation of the derived alkenes to give 9. The pivaloate group was removed and the primary alcohol was converted into sulfone 11 (Scheme 2) via the bromide 10. A modified Julia reaction between the aldehyde 12, 51, 66 and sulfone 11 gave a mixture of alkenes which was hydrogenated. The silyl ether was changed to an acetyl group as in 13, in order to avoid the presence of two identical protecting groups at a later stage, and the acetal group was converted into aldehyde 14 with periodic acid (Scheme 3).
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3 considerable precedent for the retention of the chirality. 53, [56] [57] [58] [59] Removal of the silyl group gave 17 (R= Ac, R' = Me) and hydrolysis of the two esters produced the free hydroxy acid 17 (R= H, R' = H). In the same way the enantiomer of 15, compound 18, 60 was converted into 19 and free hydroxy-MA 20 (Figure 1) . The 1 H NMR spectra of each of these in the alkene region was identical to that reported in the literature, 20, 24 and to minor signals in fractions of α-mycolates derived from M. avium.
55
Figure 1
Oxidation of either 17 (R= Ac, R' = Me) or 19 led to the corresponding protected keto-MAs. However, attempted deprotection of these using LiOH led to epimerization at the position adjacent to the ketone. In order to avoid this, the alcohol 17 (R= Ac, R' = Me) was first protected as THP-ether 21, followed by hydrolysis of the esters and then reprotection at the alcohol group as a silyl ether 22. Removal of the THP-group, oxidation, and then deprotection now proceeded without epimerization, 60 leading to the free acid 23 (Scheme 4), matching the overall structure of the major trans-alkene keto-mycolate reported for M. marinum. The chain lengths reported for major trans-alkenemethoxy-MA are somewhat different from the ketoanalogues. In order to prepare the methoxy-MA 3 (a = 17, b = 19, c = 13, d = 23), aldehyde 8 was treated with 26 and base, followed by hydrogenation to produce 27, which was in turn converted into sulfone 28 by standard methods (Scheme 6): The S-methoxy-S-methyl substituted aldehyde 32, 39 was chain extended to sulfone 34, again using standard procedures (Scheme 8): These results provide the first synthetic approaches to keto-, hydroxy-and methoxy-MAs containing a proximal (R)-α-methyl-trans-alkene unit, and a comparison of molecular rotations with those in the literature confirms the stereochemistry of this subunit. It has been proposed that MA biosynthesis involves alkylation of a cis-alkene by SAM (S-adenosylmethionine) to provides an intermediate cation leading to each of the other MA functionalities. 61 Although the actual mechanism may be different, 27 this provides a model by which to analyse the stereochemistry of the various classes of MA. Thus, using 38 as a model precursor, formal addition of a methyl cation to the distal carbon of the alkene from the bottom face would produce cation 39; trapping from the top face could lead eventually to the known (S,S)-stereochemistry of 40 at the distal position. (Scheme 9).
16, 21
Scheme 9: Formation of S,S-methoxy-MA fragment Elimination of a proton from 39 would lead to 41, and in a second step to the proximal α-methyl-trans-cyclopropane unit 42 (Scheme 10). [21] [22] [23] [24] [25] [26] 39 In this case, it appears that rapid cyclopropanation occurs, as the alkenes 41 are not commonly reported.
Scheme 10: Formation of trans-cyclopropane
In applying this to the stereochemistry of trans-alkene mycolates, one possibility is that alkylation of the cisalkene 38, again occurs from the bottom face, this time to the proximal carbon leading formally to 39b; elimination of a proton would then lead to the (R)-α-methylalkene 43 (Scheme 11). In this case, it appears that cyclopropanation of the alkene does not occur, as no such regioisomers have been reported.
Scheme 11: Proposed stereochemistry of methylation by SAM
The biological activity of mycolic acids is often seen most strongly in their sugar esters, such as glucose mycolate (GMM), TDM and TMM. 3 In natural isolates it is difficult to identify within the complex mixtures whether particular sub-classes or chain lengths are selectively responsible for these properties. To try to understand whether trans-alkene mycolic acids have specific biological properties, a series of sugar esters of the methoxy-MA 37 was prepared. The acid was first reprotected at the β-hydroxy group with TBDMS to give 44 and then coupled to the protected trehalose 45: The acid 37 was also coupled to protected glucose 52 to give, after debenzyation, the GMM 54. Like sugar esters of other synthetic alpha-, keto-and methoxy-mycolic acids, the sugar esters of trans-alkene methoxy described above show strong effects on a range of cytokines and chemokines. 63 Such sugar esters are also antigenic to antibodies in serum of patients infected with active TB. 64 The trans-alkene sugar esters described above were each evaluated as antigens in ELISA for responses to antibodies in serum of patients infected with pulmonary tuberculosis, using modified IgG(Fc) as secondary antibody to provide a colour response. Twenty samples from a WHO Specimen Bank were used, 9 culture and smear positive for TB, 11 smear and culture negative and diagnosed as not having TB. The samples were all from patients showing symptoms of suspected TB. 65 The results are presented in Table 1s (Supplementary Information) and the average responses are given in Graph 1.
Graph 1: Average responses and standard deviations for 9 serum samples from pulmonary TB, culture and smear positive patients (TB+) and 11 from culture and smear negative patients (TB0) from the WHO TDR TB specimen Bank, 65 clinically diagnosed using standard protocols in ELISA assay using IgG(Fc) secondary antibody Although the standard deviations within this small sample set are large, these results indicate that the synthetic alkene containing TDM 49 and TMM 51 may offer potential in the diagnosis of active TB. It is interesting that, for this series of compounds, the GMM 54, GroMM 60 and ArMM 57 do not show significant distinction between pulmonary TB positive or negative samples. An extended study using a large serum set is now under way to evaluate these molecules compared to other synthetic sugar mycolates as antigens in diagnosis.
3.
Experimental section 3.1 Chemicals were obtained from commercial suppliers (Sigma, Aldrich, and Alfa Aeser) or prepared from them by the methods described. Solvents which were required to be dry, e.g. ether, tetrahydrofuran were dried over sodium wire and benzophenone under nitrogen, while CH 2 Cl 2 was dried over calcium hydride. All reagents and solvents used were of reagent grade unless otherwise stated. Silica gel (Merck 7736) and silica gel plates used for column chromatography and thin layer chromatography were obtained from Aldrich; separated components were detected using variously UV light, I 2 and phosphomolybdic acid solution in IMS followed by charring. Anhydrous magnesium sulfate was used to dry organic solutions. Infra-red (IR) spectra were carried out on a Perkin-Elmer 1600 F.T.I.R. spectrometer as liquid films or KBr disc (solid). Melting points were measured using a Gallenkamp melting point apparatus. NMR spectra were carried out on a Bruker Avance 400 or 500 spectrometer. 
as a mixture of isomers in ratio 2.2:1. Palladium 10% on carbon (1.0 g) was added to a stirred solution of the alkenes (3.45 g, 3.88 mmol) in EtOAc (150 mL). Hydrogenation was carried out for 1.5 h. The solution was filtered over a bed of celite and the solvent was evaporated. Chromatography (petrol/ether, 15:1) gave a colourless oil, in dry 1,2-dimethoxyethane (20 mL) at r.t under nitrogen. The mixture was cooled to -20 °C and KHMDS (1.04 mL, 0.520 mmol, 0.5 M in toluene) was added, then allowed to reach r.t and stirred for 1.5 h. Sat. aq. NH 4 Cl (25 mL) and petrol/ ether (1:1, 50 mL) were added. The aqueous layer was re-extracted with petrol/ether (1:1, 2 × 40 mL) and the combined organic layers were evaporated. Chromatography (petrol/ether, 20:1) gave a white solid, methyl ) was added to a stirred solution of ester 17 (R = Ac, R' = Me) (30.0 mg, 0.0237 mmol) in THF (3 mL), methanol (0.5 mL) and water (0.5 mL) at RT. The mixture was stirred at 43 °C for 18 h, then cooled to RT and acidified with hydrochloric acid (5 %, 2 mL) and the aqueous layer was extracted with warm petrol/ether (1:1, 3 × 10 mL). The combined organic extracts were dried and evaporated; column chromatography (warm petrol/EtOAc, 5:1) gave a white solid, acid 17 (R = R' = H) ( ) was added to a stirred solution of the above acid (98.0 mg, 0.076 mmol) in dry DMF (1.5 mL) and dry toluene (2.5 mL) at RT followed by addition of TBDMSCl (0.110 mg, 0.756 mmol) and DMAP (14.0 mg, 0.115 mmol). The mixture was heated to 70 °C for 18 h; it was then diluted with petrol/EtOAc (1:1, 15 mL) and sat. aq. NaHCO 3 (3 mL). The aqueous layer was re-extracted with petrol/EtOAc (3 × 15 mL), and evaporated. The residue was dissolved in THF (6 mL), methanol (1.0 mL) and water (1.5 mL); to this, potassium carbonate (300 mg) was added and the mixture stirred at 45 °C for 2 h. The mixture was diluted with petrol/EtOAc (1:1, 10 mL) and water (1 mL) and acidified with potassium hydrogen sulfate to pH 6. The aqueous layer was re-extracted with petrol/EtOAc (5:2, 2 × 10 mL), the combined organic layers were dried and evaporated. Chromatography (petrol/EtOAc, 20:1) gave a colourless oil, (2R,3R,21R,39S, 40S,E)- (iv) Pyridinium-p-toluene sulfonate (PPTS) (128 mg, 0.588 mmol) was added to a stirred solution of the acid 22 (83 mg, 0.058 mmol) in THF (3 mL), and MeOH (0.5 mL) and the mixture stirred at 40 °C for 6 h, then sat. aq. NaHCO 3 (0.2 mL) was added and the product extracted with petrol/EtOAc (1:1, 3 × 10 mL). The combined organic layers were evaporated to give a crude oil; chromatography (petrol/ EtOAc, 10:1) gave a colourless oil, (2R,3R,21R,39S,40S,E)-3-((tert-butyldimethylsilyl)oxy)- 01 mg, 0.0333 mmol) . The mixture was heated to 70 °C for 18 h, then diluted with petrol/EtOAc (1:1, 15 mL) and sat. aq. NaHCO 3 (3 mL). The aqueous layer was re-extracted with petrol/EtOAc (3 × 15 mL), and the solvent evaporated. The residue was dissolved in THF (5 mL), methanol (0.5 mL) and water (0.5 mL); to this, potassium carbonate (100 mg) was added and the mixture stirred at 45 °C for 6 h, then diluted with petrol/EtOAc (1:1, 10 mL) and water (1 mL) and acidified with potassium hydrogen sulfate to pH 2. The aqueous layer was re-extracted with petrol/EtOAc (1:1, 2 × 10 mL), and the combined organic layers dried and the solvent evaporated. Chromatography (petrol/EtOAc, 20:1) gave a colourless oil, (2R,3R,21R,39R, mg, 0.118 mmol) was added to a stirred solution of the above acid (17.3 mg, 0.0118 mmol) in THF (1 mL), methanol (0.1 mL) and water (0.1 mL) and the mixture refluxed for 2.5 h followed by stirring at 47 °C for 24 h, then sat. aq. NaHCO 3 (0.2 mL) was added and the product extracted with petrol/EtOAc (1:1, 3 × 5 mL). The combined organic layers were evaporated to give an oil; chromatography eluting with petrol/EtOAc (10:1) gave a colourless oil, (2R,3R,21R,39R,40R,E)-3-((tert-butyldimethylsilyl)-oxy)-2-docosyl-39-hydroxy-21,40-dimethyloctapentacont-22-enoic acid ( 4 Cl (100 mL) were added, the organic layer was separated and the aq. layer was extracted with petrol/ether (1:1, 2 × 100 mL). The combined organic layers were evaporated. Chromatography (petrol/ether, 50:1) gave a colourless oil, (E/Z)(R)-12-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)tridec-9-en-1-yl pivaloate 14 g, 76% in ratio (2.5:1). Palladium 10 % on carbon (1 g) was stirred with the above alkenes (14 g, 36 mmol) in IMS (200 mL) under hydrogen for 2 h. The solution was filtered on a bed of celite and evaporated to give a colourless oil of the title compound 27 (13 g R)-12-((S)-2,2-Dimethyl-1,3-dioxolan-4-yl) tridecyl)sulfonyl)-1-phenyl-1H-tetrazole 28 (i) A solution of (R)-12-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)tridecyl pivaloate 27 (12.7 g, 33.1 mmol) in dry THF (100 mL) was added slowly to a stirred suspension of LiAlH 4 (1.88 g, 49.6 mmol) at -20 o C under nitrogen. The mixture was heated under reflux for 1h, then quenched with sat. aq. Na 2 SO 4 (10 mL) at -10 o C, stirred until a white precipitate formed, then MgSO 4 (20 g) was added. The precipitate was filtered through celite and washed with THF (2 × 50 mL). Column chromatography (5:1 petrol/ ether) gave a colourless oil, (R)-12-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-tridecan-1-ol (8.0 g, 81%) , 2-((1R,15R)-1-((tert-butyldimethylsilyl)-oxy)-15-((S)-2,2-dimethyl-1,3-dioxolan-4-yl) hexadecyl)-hexacosanoate 30 LiHMDS (9.3 mL, 9.9 mmol, 1.06 M) was added to a stirred solution of sulfone 28 (3.23 g, 6.57 mmol) and ester 29 (3.27 g, 5.49 mmol) 43 in dry THF (50 mL) at -10 o C under nitrogen. The mixture was allowed to reach r. t., stirred for 2 h, then quenched with sat. aq. NH 4 Cl (100 mL) and diluted with petrol/ether (100 mL). The organic phase was separated and the aqueous layer was extracted with petrol/ether (1:1, 2 × 100 mL). The combined organic layers were dried and tevaporated. Chromatography (15:1 petrol/ether) gave a colourless oil, methyl (E/Z)-(2R)-2- ((1R,15R)-1-((tert-butyldimethylsilyl)oxy)-15-(2,2-dimethyl-1,3-dioxolan-4-yl)hexadec-3-en-1-yl) hexacosanoate 4.5 g, 96% as a 2.5: 1 mixture. Palladium (10% on carbon, 1.0 g) was added to the above alkenes (4.5 g, 5.21 mmol) in EtOAc (150 mL) under hydrogen and stirred for 1.5 h. The solution was filtered over celite and evaporated. Chromatography (petrol/ether, 15:1) gave a colourless oil, the title compound 30 (4.3 g, 96%) , [ 2-((1R,15R)-1-((tert-butyldimethylsilyl) 70H, m), 1.20 (9H, s), 1.12 -1.06 (1H, m) (ii) The ester 35 (0.70 mg, 0.05 mmol) was dissolved in dry THF (10 mL) in a dry polyethylene vial under nitrogen at r.t. and stirred. Pyridine (0.07 mL) and HF-pyridine complex (0.5 mL) were added; the mixture was stirred for 17 h. at 42 °C, neutralized with sat. aq. NaHCO 3 18 mmol) in dry DMF (1.5 mL) and dry toluene (2.5 mL) at r. t. followed by the addition of TBDMSCl (0.27 g, 1.8 mmol) and DMAP (10 mg). The mixture was stirred at 70 o C for 24 h. The solvent was evaporated under reduced pressure and the residue was diluted with EtOAc (50 mL) and water (20 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (2 × 30 mL). The combined organic layers were washed with water, dried and evaporated to give a colourless oil. The residue was dissolved in THF (8 mL) and n-Bu 4 NOH (0.9 mL, 4%) and stirred for 10 min. at r. t. then diluted with water (10 mL) and extracted with EtOAc (2 × 20 mL), dried and evaporated to give a residue; column chromatography (petroleum/EtOAc, 20:1) gave a colourless oil, the title compound 44 (0.25 
(R)-2-((1R
,(2R,3R,21R,39S,40S,E)-3-acetoxy-39-((tert-butyl- dimethylsilyl)oxy)-2-docosyl-21,40-dimethyloctapenta- cont
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
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(2R,3R,21R,39R,40R,E)-2-Docosyl-3,39-dihydroxy-21,40-dimethyloctapentacont-22-enoic acid 20 (R = R' = H)
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